<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155749</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-101</org_study_id>
    <nct_id>NCT04155749</nct_id>
  </id_info>
  <brief_title>Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma</brief_title>
  <official_title>Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcellx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcellx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Master protocol for cell therapy, Phase 1 proof-of-concept studies., in relapsed and
      refractory multiple myeloma and includes long-term safety follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ARM 1 is a, non-randomized, open label, multi-site Phase 1 study. CART-ddBCMA is a BCMA
      directed CAR with a non-scFv binding domain that has been deimmunized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs), including DLT(s)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) and ORR by IMWG Consensus Criteria</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Relapsed and Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CART-ddBCMA</intervention_name>
    <description>Chimeric Antigen Receptor T cells</description>
    <arm_group_label>ARM 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of
             system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and
             anti-CD38 antibody (CD38mab); or has &quot;triple-refractory&quot; disease

          -  Documented measurable disease

          -  Adequate organ function

          -  Life expectancy &gt; 12 weeks, Eastern Cooperative Group Performance Status 0-1

        Exclusion Criteria:

          -  Plasma Cell Leukemia or History of Plasma Cell Leukemia

          -  Patients with a history of severe hypersensitivity to DMSO should be excluded

          -  Contraindication to fludarabine or cyclophosphamide

          -  Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities

          -  Active central nervous system disease involvement by malignancy or active CNS
             pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arcellx, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Arcellx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arcellx, Inc.</last_name>
    <phone>240-327-0379</phone>
    <email>clinical@arcellx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Sheppard, BSN, RN</last_name>
      <phone>773-702-2476</phone>
      <email>melissa.sheppard@uchospitals.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Malloy, RN, BSN</last_name>
      <phone>773-834-1475</phone>
      <email>rmallow@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Bishop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Frigault, MD</last_name>
      <phone>617-724-4000</phone>
    </contact>
    <investigator>
      <last_name>Matthew Frigault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCMA</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Chimeric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

